Genmab vets at low-profile Y-mAbs steer two MSK cancer drugs to the FDA after landing $50M from HBM
Almost exactly two years ago, a group of Genmab veterans formed a biotech company called Y-mAbs in New York, launching with a pair of clinical-stage cancer drugs snared from scientists at Memorial Sloan-Kettering.
Today, just a few months after grabbing a breakthrough drug designation for the lead therapy in the licensing pact, Y-mAbs is back with a $50 million raise from HBM, a prominent biotech investor. And it’s aiming for a near-term FDA approval of burtomab and its other drug from MSK, naxitamab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.